2022 at a glance
See all highlights10.0 bn
Invested in research & development (USD)
(vs. USD 9.5 bn in 2021)
23
Approvals in the US, EU, China and Japan
for new medicines and new indications for existing medicines
(vs. 21 in 2021)
54.6 m
Patients reached through access programs
predominantly in low- and middle-income countries (LMICs)
(vs. 56.2 m in 2021)
50.5 bn
Net sales (USD)
(vs. USD 51.6 bn in 2021)
Who we are
Novartis is one of the world’s leading medicines companies. We use innovative science and technology to address some of society’s most challenging healthcare issues.
How we create value
Through our core business, we improve and extend the lives of millions of people around the world, while creating value for our employees, shareholders and the communities in which we operate.
Innovation
Operations and supply chain
Access for patients
Social, financial & economic value
Innovation
Operations and supply chain
Access for patients
Social, financial & economic value
CEO’s letter
As we look to the future as a focused medicines company, our dedication to innovation and excellence will drive us forward.
Our performance in 2022
Read about our performance against our strategy and our financial performance below.
Deliver high-value medicines to accelerate growth
Embed operational excellence to deliver returns
Strengthen our foundations:
-
Unleash the power of our people
Learn more -
Scale data science and technology
Learn more -
Build trust with society
Learn more
Financial performance: Novartis maintained its growth momentum in 2022.
Filter our online integrated report by key topics: